ResMed | RMD - Equity Capital And Reserves


ResMed reported $6.59B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Ansell USD 1.97B 10.2M Dec/2025
Artivion USD 445.58M 4.88M Jun/2026
AtriCure USD 516.43M 24.74M Jun/2026
Baxter International USD 6.21B 163M Jun/2026
Cochlear AUD 1.94B 12.2M Dec/2025
Cooper Companies USD 8.33B 89.1M Jun/2026
CSL USD 18.66B 2.75B Dec/2025
Dexcom USD 2.62B 335.5M Jun/2026
Edwards Lifesciences USD 10.62B 290.5M Jun/2026
Fisher Paykel Healthcare NZD 2.12B 129.2M Jun/2026
Globus Medical USD 4.77B 36.29M Jun/2026
Haemonetics USD 837.1M 40.78M Jun/2026
Idexx Laboratories USD 1.61B 56.47M Jun/2026
Inogen USD 197.18M 2.32M Sep/2025
Insulet USD 1.42B 119.6M Jun/2026
Integra LifeSciences USD 1.04B 971K Jun/2026
Intuitive Surgical USD 18.17B 693.9M Jun/2026
Medtronic USD 50.23B 160M Jun/2026
Philips EUR 11.48B 84M Jun/2026
Ramsay Health Care AUD 4.79B 916.1M Dec/2025
ResMed USD 6.59B 93.48M Jun/2026
Sigma Healthcare AUD 4.67B 3.8B Dec/2025
Sonic Healthcare AUD 8.2B 120.9M Dec/2024
Steris USD 7.21B 23.1M Jun/2026
Teleflex USD 2.9B 179.9M Jun/2026
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026